Green Square Capital LLC cut its holdings in Pfizer, Inc. (NYSE:PFE) by 91.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,724 shares of the biopharmaceutical company’s stock after selling 120,557 shares during the quarter. Green Square Capital LLC’s holdings in Pfizer were worth $367,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Fisher Asset Management LLC raised its position in Pfizer by 1.7% in the first quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock worth $1,120,704,000 after acquiring an additional 554,777 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after acquiring an additional 377,404 shares in the last quarter. Macquarie Group Ltd. raised its position in Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after acquiring an additional 228,405 shares in the last quarter. Boston Partners raised its position in Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after acquiring an additional 1,649,801 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Pfizer by 1.0% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 17,376,931 shares of the biopharmaceutical company’s stock worth $594,465,000 after acquiring an additional 169,073 shares in the last quarter. Hedge funds and other institutional investors own 69.09% of the company’s stock.

Several brokerages have commented on PFE. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a research report on Wednesday. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. BMO Capital Markets reiterated a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research report on Wednesday, September 6th. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Finally, Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Monday, July 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average price target of $37.72.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/13/green-square-capital-llc-reduces-holdings-in-pfizer-inc-pfe.html.

Shares of Pfizer, Inc. (PFE) traded down 0.777% during midday trading on Wednesday, hitting $35.095. The stock had a trading volume of 8,462,375 shares. The company has a market capitalization of $208.72 billion, a PE ratio of 25.673 and a beta of 1.00. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.43. The firm’s 50-day moving average is $33.38 and its 200 day moving average is $33.49.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $0.64 earnings per share. Equities analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were given a $0.32 dividend. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. Pfizer’s payout ratio is 94.12%.

In other news, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at $19,730,812. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 426,291 shares of company stock valued at $14,475,911. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.